
Biocept BIOC
Quarterly report 2023-Q2
added 08-14-2023
Biocept Total Liabilities 2011-2026 | BIOC
Annual Total Liabilities Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 M | 22.9 M | 23.8 M | 6.53 M | 5.71 M | 6.08 M | 6.92 M | 6.89 M | 6.81 M | 13.8 M | 28.9 M | 17.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.9 M | 5.71 M | 14 M |
Quarterly Total Liabilities Biocept
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 M | 20.6 M | 22 M | 23.6 M | 25.7 M | 24.9 M | 22.9 M | 22.9 M | 21.3 M | 23.5 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 6.53 M | 6.53 M | 6.53 M | 6.53 M | 5.71 M | 5.71 M | 5.71 M | 5.71 M | 6.08 M | 6.08 M | 6.08 M | 6.08 M | 6.92 M | 6.92 M | 6.92 M | 6.92 M | 6.89 M | 6.89 M | 6.89 M | 6.89 M | 6.79 M | 6.79 M | 6.79 M | 6.79 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.7 M | 5.71 M | 12.7 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
14.4 M | $ 22.11 | - | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | ||
|
Burning Rock Biotech Limited
BNR
|
433 M | $ 22.36 | 17.07 % | $ 241 M | ||
|
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.6 | - | $ 2.03 M | ||
|
Castle Biosciences
CSTL
|
75.4 M | $ 40.61 | 1.35 % | $ 1.13 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M | ||
|
Co-Diagnostics
CODX
|
9.31 M | $ 6.03 | - | $ 177 M | ||
|
DarioHealth Corp.
DRIO
|
7.26 M | $ 12.13 | -10.01 % | $ 344 M | ||
|
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | ||
|
Fulgent Genetics
FLGT
|
90.8 M | $ 28.01 | 7.77 % | $ 847 M | ||
|
Danaher Corporation
DHR
|
31.8 B | $ 235.57 | - | $ 172 B | ||
|
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | ||
|
DexCom
DXCM
|
4.2 B | $ 70.1 | - | $ 27.1 B | ||
|
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | ||
|
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | ||
|
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | ||
|
Exact Sciences Corporation
EXAS
|
3.53 B | $ 101.63 | - | $ 18.8 B | ||
|
CareDx, Inc
CDNA
|
205 M | $ 18.9 | - | $ 1.02 B | ||
|
Celcuity
CELC
|
130 M | $ 109.17 | 3.95 % | $ 4.31 B | ||
|
Anixa Biosciences
ANIX
|
2.7 M | $ 3.28 | - | $ 105 K | ||
|
Guardant Health
GH
|
1.63 B | $ 109.93 | - | $ 13.5 B | ||
|
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
20.8 B | $ 244.29 | 1.58 % | $ 44.3 B | ||
|
Illumina
ILMN
|
2.7 B | $ 150.14 | - | $ 23.9 B | ||
|
Charles River Laboratories International
CRL
|
4.02 B | $ 216.77 | - | $ 11.1 B | ||
|
Mettler-Toledo International
MTD
|
3.37 B | $ 1 470.87 | - | $ 31.2 B | ||
|
Myriad Genetics
MYGN
|
326 M | $ 6.63 | - | $ 601 M | ||
|
National Research Corporation
NRC
|
73.5 M | $ 18.9 | -2.07 % | $ 464 M | ||
|
Natera
NTRA
|
689 M | $ 254.4 | - | $ 25 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 178.14 | - | $ 19.8 B | ||
|
Biodesix
BDSX
|
76.4 M | $ 5.96 | -1.16 % | $ 773 M | ||
|
OPKO Health
OPK
|
835 M | $ 1.36 | - | $ 944 M | ||
|
Laboratory Corporation of America Holdings
LH
|
10.3 B | $ 253.73 | - | $ 21.3 B | ||
|
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | ||
|
ICON Public Limited Company
ICLR
|
7.35 B | $ 202.92 | - | $ 16.7 B | ||
|
IDEXX Laboratories
IDXX
|
1.7 B | $ 714.55 | - | $ 58.9 B | ||
|
Lantheus Holdings
LNTH
|
892 M | $ 69.37 | -0.44 % | $ 4.8 B | ||
|
Agilent Technologies
A
|
5.32 B | $ 147.81 | 0.14 % | $ 44.9 B | ||
|
Biomerica
BMRA
|
1.84 M | $ 2.78 | 5.41 % | $ 6.39 M | ||
|
Bioventus
BVS
|
590 M | $ 7.61 | -0.52 % | $ 477 M | ||
|
Koninklijke Philips N.V.
PHG
|
16.9 B | $ 29.12 | - | $ 20 B | ||
|
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |